No Data
No Data
After on-site inspections of the sixth company this month, TAILIN and the Director received a warning letter | Quick read of the announcement.
① During the on-site inspection, issues such as insufficient production capacity for some public fundraising projects were discovered, resulting in TAILIN and related responsible persons receiving a warning letter from the Zhejiang Securities Regulatory Bureau; ② At the end of 2024, TAILIN had previously postponed the public fundraising project "Cell Therapy Industrial Equipment Manufacturing Base Project" by six months; ③ This is the sixth listed company warned after being inspected by the local Securities Regulatory Bureau this month.
TAILIN (300813.SZ) received a warning letter from the Zhejiang Securities Regulatory Bureau.
TAILIN Bio (300813.SZ) announced that the company recently received a notice from the Zhejiang Securities Regulatory Bureau regarding Zhejiang TAILIN...
TAILIN (300813.SZ): Plans to postpone the "Cell Therapy Industrialization Equipment Manufacturing Base Project" until June 30, 2025.
Gelonghui, December 31丨TAILIN (300813.SZ) announced that the company will hold the fifth meeting of the fourth Board of Directors and the fifth meeting of the fourth Supervisory Board on December 31, 2024. The proposal concerning the extension of the fundraising for the issuance of Convertible Bonds to unspecified entities was reviewed and approved. Under the condition that the investment project主体, implementation location, investment purpose, and investment scale do not change, based on the current actual construction progress of the fundraising investment project, the fundraising for the Convertible Bonds will be allocated to the "Cell Therapy Industrialization Equipment Manufacturing Base Project" to reach the predetermined usable state.
Revenues Not Telling The Story For Zhejiang Tailin BioEngineering Co.,Ltd (SZSE:300813) After Shares Rise 26%
Beyond Lackluster Earnings: Potential Concerns For Zhejiang Tailin BioEngineeringLtd's (SZSE:300813) Shareholders
Tailin Biotech: Report for the third quarter of 2024
Optimistic Investors Push Zhejiang Tailin BioEngineering Co.,Ltd (SZSE:300813) Shares Up 28% But Growth Is Lacking
